Other research analysts have also recently issued research reports about the company. UBS raised GlaxoSmithKline to a buy rating and set a GBX 1,550 ($21.41) price target on the stock in a research report on Monday, November 27th. Berenberg Bank reaffirmed a buy rating and set a GBX 1,760 ($24.32) price target on shares of GlaxoSmithKline in a research report on Wednesday, December 13th. Liberum Capital reaffirmed a buy rating and set a GBX 1,760 ($24.32) price target on shares of GlaxoSmithKline in a research report on Monday, January 15th. Jefferies Group reaffirmed a buy rating and set a GBX 1,500 ($20.72) price target on shares of GlaxoSmithKline in a research report on Tuesday, January 16th. Finally, Beaufort Securities raised GlaxoSmithKline to a buy rating and upped their price target for the company from GBX 1,450 ($20.03) to GBX 1,500 ($20.72) in a research report on Thursday, February 8th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The company currently has an average rating of Hold and an average price target of GBX 1,529.55 ($21.13).
GlaxoSmithKline (GSK) opened at GBX 1,288.20 ($17.80) on Friday. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.07) and a 1 year high of GBX 1,724.50 ($23.83). The company has a market capitalization of $65,630.00 and a price-to-earnings ratio of 2,430.57.
In other GlaxoSmithKline news, insider Patrick Vallance sold 14,022 shares of the company’s stock in a transaction dated Monday, February 19th. The stock was sold at an average price of GBX 1,318 ($18.21), for a total value of £184,809.96 ($255,332.91). Also, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was acquired at an average price of GBX 1,278 ($17.66) per share, for a total transaction of £7,182.36 ($9,923.13). Over the last 90 days, insiders acquired 591 shares of company stock worth $756,678 and sold 23,765 shares worth $31,152,709.
COPYRIGHT VIOLATION NOTICE: “GlaxoSmithKline (GSK) Given a GBX 1,750 Price Target by Goldman Sachs Analysts” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3303638/glaxosmithkline-gsk-given-a-gbx-1750-price-target-by-goldman-sachs-analysts.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.